

Triptolide

Catalog No: tcsc0286



Available Sizes

Size: 2mg

Size: 5mg

Size: 10mg

Size: 25mg

Size: 100mg



Specifications

CAS No:

38748-32-2

Formula:

$C_{20}H_{24}O_6$

Pathway:

NF-κB

Target:

NF-κB

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 33 mg/mL (91.56 mM)

Alternative Names:

PG490

Observed Molecular Weight:

360.4

Product Description


Triptolide is a diterpenoid triepoxide extracted from the root of *Tripterygium wilfordii* with immunosuppressive, anti-inflammatory and antiproliferative effects. Triptolide is a **NF-κB** activation inhibitor.

IC50 & Target: heat shock factor (HSF1)^[1]

IC50: 47 to 73 nM (MDM2, in ALL cell lines)^[2]

In Vitro: Triptolide induces apoptosis in cultured and primary Chronic Lymphocytic Leukemia (CLL) B-cells. Treatment of CD19⁺ B cells with Triptolide, induces a dose-dependent increase in apoptosis in cultured and primary CLL cells. Triptolide is selectively toxic to both high risk (n=5) and low risk CLL (n=12) B cells (10 to 50 nM range) while largely sparing normal B-cells (n=5). Consistent with the inhibition of heat-shock induced HSP transcription, treatment with Triptolide attenuates heat-shock induced expression of HSPs^[1]. Triptolide is a natural product derived from the Chinese plant *Tripterygium wilfordii*, is reported to exhibit antitumor effects in a broad range of cancers. Triptolide inhibits MDM2 expression in a dose-dependent manner, even at low concentrations spanning 20-100 nM in acute lymphoblastic leukemia (ALL) cells. Triptolide exhibits strongly cytotoxic activity in all 8 cell lines having native MDM2 overexpression, with IC₅₀ values range from 47 to 73 nM. Triptolide exhibits much less cytotoxic effect on EU-4 cells that express very low level of MDM2, while it effectively kill these cells when MDM2 is stably transfected (IC₅₀ values: 725 nM vs. 88 nM)^[2]. Differentiated PC12 cells are incubated with different concentrations of Triptolide (0.01, 0.1, and 1 nM) in the presence of 10 μM Aβ₂₅₋₃₅ for 24 hours and MTT assay is used to detect the effect of Triptolide. The results show that Aβ₂₅₋₃₅ can decrease the cell viability and when treated with Triptolide the viability of differentiated PC12 cells is significantly increased. The results indicate that Triptolide can alleviate cellular damage caused by Aβ₂₅₋₃₅, which means that Triptolide has a neuroprotective effect^[3].

In Vivo: The Triptolide (TP) plasma concentrations are declined rapidly in mice after receive an intravenous dose. After 2h of injection, the Triptolide concentrations are dropped below the lower limit of quantification for all three groups. A comparison of the parameters is made between the control and the treated groups to assess the effect of P-gp inhibition on the Triptolide exposure and elimination. Treatment with the *mdr1a*-siRNA can significantly enhance the Triptolide plasma exposure, with the C_{max} increases from 413±74 to 510±94 ng/mL (P[4]).



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!